Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NCK1 | P16333 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8268977 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CYP1A2LMNANCK1BACE1 | |
| SCHEMBL434860 | 0.84 | CYP1A2 (0.57) | ALDH1A1CYP1A2LMNAMEN1KMT2A | |
| SCHEMBL4572536 | 0.83 | CYP1A2 (0.65) | ALDH1A1CYP1A2NCK1BACE1PDE3B | |
| SCHEMBL24261121 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2NCK1BACE1PDE3B | |
| SCHEMBL2000504 | 0.76 | MAP4K4 (0.54) | ALDH1A1CYP1A2NCK1BACE1CYP2A6 | |
| SCHEMBL16289890 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2NCK1BACE1PDE3B | |
| SCHEMBL5509853 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2NCK1BACE1PDE3B | |
| SCHEMBL2002584 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2LMNANCK1BACE1 | |
| SCHEMBL16962242 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2NCK1BACE1PDE3B | |
| SCHEMBL1359776 | 0.76 | MAP4K4 (0.46) | ALDH1A1PDE3BPDE3AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2988597-B1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | HARVARD COLLEGE (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20170305953-A1 | 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016161176-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016154591-A1 | MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016057798-A1 | 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2014165792-A2 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305953-A1 | 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP51A1, HSD17B7, CYP11B1 | ALDH1A1 1733/4885CYP1A2 117/4885LMNA 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.